Disparate Outcomes in Hispanic Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease/Steatohepatitis and Type 2 Diabetes: Large Cohort Study

Authors

• Joseph Matthew Gosnell
• George Golovko
• Esteban Arroyave
• Akshata Moghe
• Michael L Kueht
• Omar Abdul Saldarriaga
• Kevin H McKinney
• Heather L Stevenson
• Monique R Ferguson

Language

English

Publication Date

5-15-2024

Journal

World Journal of Diabetes

DOI

10.4239/wjd.v15.i5.886

PMID

38766421

PMCID

PMC11099377

PubMedCentral® Posted Date

5-15-2024

PubMedCentral® Full Text Version

Post-print

Abstract

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are a growing health burden across a significant portion of the global patient population. However, these conditions seem to have disparate rates and outcomes between different ethnic populations. The combination of MASLD/MASH and type 2 diabetes increases the risk of hepatocellular carcinoma (HCC), and Hispanic patients experience the greatest burden, particularly those in South Texas.

Aim: To compare outcomes between Hispanic and non-Hispanic patients in the United States, while further focusing on the Hispanic population within Southeast Texas to determine whether the documented disparity in outcomes is a function of geographical circumstance or if there is a more widespread reason that all clinicians must account for in prognostic consideration.

Methods: This cohort analysis was conducted with data obtained from TriNetX, LLC ("TriNetX"), a global federated health research network that provides access to deidentified medical records from healthcare organizations worldwide. Two cohort networks were used: University of Texas Medical Branch (UTMB) hospital and the United States national database collective to determine whether disparities were related to geographic regions, like Southeast Texas.

Results: This study findings revealed Hispanics/Latinos have a statistically significant higher occurrence of HCC, type 2 diabetes mellitus, and liver fibrosis/cirrhosis in both the United States and the UTMB Hispanic/Latino groups. All-cause mortality in Hispanics/Latinos was lower within the United States group and not statistically elevated in the UTMB cohort.

Conclusion: This would appear to support that Hispanic patients in Southeast Texas are not uniquely affected compared to the national Hispanic population.

Keywords

Metabolic dysfunction-associated steatotic liver disease, Metabolic dysfunction-associated steatohepatitis, Hispanic, Diabetes mellitus, TriNetX, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis, Steatotic liver disease, Hepatocellular carcinoma

Published Open-Access

yes

Recommended Citation

Gosnell, Joseph Matthew; Golovko, George; Arroyave, Esteban; et al., "Disparate Outcomes in Hispanic Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease/Steatohepatitis and Type 2 Diabetes: Large Cohort Study" (2024). Faculty, Staff and Student Publications. 3664.
https://digitalcommons.library.tmc.edu/uthmed_docs/3664